Tongfeng Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tongfeng Chen has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Chuanyu Gao
Department of Cardiology, Central China Subcenter of National Center forCardiovascular Diseases, Henan Cardiovascular Disease Center, Fuwai Central ChinaCardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, China
3 shared publications Yuhao Liu
Department of Cardiology , Fuwai Central China Cardiovascular Hospital , Central China Fuwai Hospital of Zhengzhou University , Zhengzhou , 451464 , Henan , China
3 shared publicationsJing Zhang
Henan Key Laboratory of Coronary Heart Disease Control, Heart Center of Henan Provincial People's Hospital, Henan Research Center for Cardiovascular Epidemiology, Central China Fuwai Hospital People's Hospital of Zhengzhou University Zhengzhou China
2 shared publicationsYu Han
Henan Key Laboratory of Coronary Heart Disease Control, Heart Center of Henan Provincial People's Hospital, Henan Research Center for Cardiovascular Epidemiology, Central China Fuwai Hospital People's Hospital of Zhengzhou University Zhengzhou China
2 shared publicationsZirui Sun
Henan Key Laboratory of Coronary Heart Disease Control, Heart Center of Henan Provincial People's Hospital, Henan Research Center for Cardiovascular Epidemiology, Central China Fuwai Hospital People's Hospital of Zhengzhou University Zhengzhou China
2 shared publicationsBiao Cheng
1 shared publication
Latest Publications
- Open Access
Single vs Double ProGlide Devices for Access Site Closure after Transfemoral Aortic Valve Replacement
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , 5407966
Pan‐Immune‐Inflammation Value: Related to Perforation Diameter and Pulmonary Artery Pressure in Ventricular Septal Rupture Patients
Objective: This study investigated the relationship between the pan‐immune‐inflammation value (PIV) and the perforation diameter in patients with ventricular septal rupture (VSR), as well as the changes in pulmonary artery systolic pressure ( Δ PASP) after transcatheter closure. Methods: The clinical data from 133 VSR patients who underwent transcatheter closure were analyzed. Patients were divided into high and low PIV groups based on a median cutoff value of 6. Boruta was used for exploratory variable screening; prespecified covariate sets were used for adjusted models. A generalized additive model (GAM) was used to explore the potential nonlinear relationships. Where a nonlinear association was suggested by the GAM, a piecewise linear regression model was subsequently fitted to precisely quantify the threshold effects and the differential associations of PIV/100 with Δ PASP and perforation diameter on either side of the identified inflection point. Results: One hundred thirty‐three patients with VSR (mean age 67 years, 50.6% female) were enrolled. Linear regression showed no statistically significant association between PIV/100 and Δ PASP. GAM suggested a possible nonlinear pattern between PIV/100 and Δ PASP (and perforation diameter). In piecewise models, an inverse association was observed above the break point, but this pattern was attenuated after multivariable adjustment and in sensitivity analyses. In discrimination analyses, adding PIV/100 to the baseline model yielded a modest numerical increase in AUC, but the incremental gain was not statistically significant. Conclusion: PIV may serve as an adjunct inflammatory marker in VSR patients undergoing transcatheter closure; however, the break point findings are exploratory and the incremental predictive value warrants validation in larger, independent cohorts with better adjudication of infection/systemic inflammation.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , 5407966
Open AccessPan‐Immune‐Inflammation Value: Related to Perforation Diameter and Pulmonary Artery Pressure in Ventricular Septal Rupture Patients
Objective: This study investigated the relationship between the pan‐immune‐inflammation value (PIV) and the perforation diameter in patients with ventricular septal rupture (VSR), as well as the changes in pulmonary artery systolic pressure ( Δ PASP) after transcatheter closure. Methods: The clinical data from 133 VSR patients who underwent transcatheter closure were analyzed. Patients were divided into high and low PIV groups based on a median cutoff value of 6. Boruta was used for exploratory variable screening; prespecified covariate sets were used for adjusted models. A generalized additive model (GAM) was used to explore the potential nonlinear relationships. Where a nonlinear association was suggested by the GAM, a piecewise linear regression model was subsequently fitted to precisely quantify the threshold effects and the differential associations of PIV/100 with Δ PASP and perforation diameter on either side of the identified inflection point. Results: One hundred thirty‐three patients with VSR (mean age 67 years, 50.6% female) were enrolled. Linear regression showed no statistically significant association between PIV/100 and Δ PASP. GAM suggested a possible nonlinear pattern between PIV/100 and Δ PASP (and perforation diameter). In piecewise models, an inverse association was observed above the break point, but this pattern was attenuated after multivariable adjustment and in sensitivity analyses. In discrimination analyses, adding PIV/100 to the baseline model yielded a modest numerical increase in AUC, but the incremental gain was not statistically significant. Conclusion: PIV may serve as an adjunct inflammatory marker in VSR patients undergoing transcatheter closure; however, the break point findings are exploratory and the incremental predictive value warrants validation in larger, independent cohorts with better adjudication of infection/systemic inflammation.
- Open Access
Transcatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
Objective Examine the cost-effectiveness of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for Chinese patients with severe aortic stenosis (AS) at intermediate and high surgical risk. Design A two-phase model, comprising a 1-month decision tree to simulate perioperative outcomes and a 5-year Markov model with monthly cycles to simulate long-term outcomes, has been developed to evaluate the cost-effectiveness of TAVI compared with SAVR for Chinese patients with AS at intermediate and high risk. The event rates for both phases are sourced from the Placement of Aortic Transcatheter Valves IA and IIA trials, while the cost inputs and utility values are sourced from local sources or published literature. Adjustments for inflation were made using consumer price indexes for healthcare to enhance precision. To ensure the reliability and robustness of the model, sensitivity analyses were conducted to assess their impact on outcomes. Setting China healthcare system perspective. Participants A hypothetical cohort of Chinese patients with AS in intermediate and high surgical risk. Interventions TAVI versus SAVR. Outcome measures Cost, quality-adjusted life-years (QALYs), life-years gained and incremental cost-effectiveness Ratio (ICER). Result For both intermediate- and high-risk AS patients, offering TAVR resulted in high healthcare costs but moderate benefits compared with SAVR. Specifically, in the intermediate-risk population, TAVR led to a 0.34 QALY increase over SAVR, with an incremental cost of $16 707.58, resulting in an ICER of $49 176.60/QALY. Similarly, in the high-risk population, TAVR showed a 0.15 QALY increase over SAVR, with an incremental cost of $18 093.52, leading to an ICER of $122 696.37/QALY. However, both ICERs exceeded the willingness-to-pay threshold of $37 654.50/QALY. Sensitivity analyses confirmed the model’s stability under parameter uncertainty. Conclusion TAVI was deemed not cost-effective compared with SAVR for patients with AS at intermediate or high surgical risk in the Chinese healthcare system. Lowering valve costs was considered an effective approach to improve the cost-effectiveness of TAVI.
Open AccessTranscatheter aortic valve implantation versus surgical aortic valve replacement in Chinese patients with intermediate and high surgical risk for aortic stenosis: a decision analysis on effect, affordability and cost-effectiveness
Objective Examine the cost-effectiveness of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for Chinese patients with severe aortic stenosis (AS) at intermediate and high surgical risk. Design A two-phase model, comprising a 1-month decision tree to simulate perioperative outcomes and a 5-year Markov model with monthly cycles to simulate long-term outcomes, has been developed to evaluate the cost-effectiveness of TAVI compared with SAVR for Chinese patients with AS at intermediate and high risk. The event rates for both phases are sourced from the Placement of Aortic Transcatheter Valves IA and IIA trials, while the cost inputs and utility values are sourced from local sources or published literature. Adjustments for inflation were made using consumer price indexes for healthcare to enhance precision. To ensure the reliability and robustness of the model, sensitivity analyses were conducted to assess their impact on outcomes. Setting China healthcare system perspective. Participants A hypothetical cohort of Chinese patients with AS in intermediate and high surgical risk. Interventions TAVI versus SAVR. Outcome measures Cost, quality-adjusted life-years (QALYs), life-years gained and incremental cost-effectiveness Ratio (ICER). Result For both intermediate- and high-risk AS patients, offering TAVR resulted in high healthcare costs but moderate benefits compared with SAVR. Specifically, in the intermediate-risk population, TAVR led to a 0.34 QALY increase over SAVR, with an incremental cost of $16 707.58, resulting in an ICER of $49 176.60/QALY. Similarly, in the high-risk population, TAVR showed a 0.15 QALY increase over SAVR, with an incremental cost of $18 093.52, leading to an ICER of $122 696.37/QALY. However, both ICERs exceeded the willingness-to-pay threshold of $37 654.50/QALY. Sensitivity analyses confirmed the model’s stability under parameter uncertainty. Conclusion TAVI was deemed not cost-effective compared with SAVR for patients with AS at intermediate or high surgical risk in the Chinese healthcare system. Lowering valve costs was considered an effective approach to improve the cost-effectiveness of TAVI.
- Open Access
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
Objective This study aimed to investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody camrelizumab to first-line platinum-doublet chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (L/M NPC) from the perspective of Chinese healthcare system. Design A Markov model consisting of four health states, progression-free survival, first progression survival, second progression survival and death, was built to simulate 3-week patient transitions over a 20-year horizon. A direct comparison between first-line camrelizumab in combination with gemcitabine plus cisplatin and gemcitabine plus cisplatin was performed by calculating transition probabilities from the CAPTAIN-1st trial. Costs and utilities were collected from the local public database and literature. One-way and probabilistic sensitivity analyses were employed to evaluate the robustness of the model. Setting The Chinese healthcare system perspective. Participants A hypothetical cohort of Chinese patients with pathologically diagnosed L/M NPC who had an Eastern Cooperative Oncology Group performance status of 0 or 1. Interventions First-line camrelizumab in combination with camrelizumab and gemcitabine plus cisplatin (CGP) versus gemcitabine plus cisplatin (GP). Primary outcome measure Cost, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER). Results The baseline analysis demonstrated that, compared with first-line GP, first-line CGP yields an effectiveness increase of 0.26 QALY, accompanied by an increment of US$6137.59 in healthcare cost. This results in an ICER of US$23 482.32/QALY. With the willingness-to-pay (WTP) threshold for a QALY set at US$37 654.50, first-line CGP proves to be cost-effective in 97.20% of the iterations. Deterministic sensitivity analyses indicated that the uncertainty in model parameters had no substantial effect on our results. Probability sensitivity analysis indicated that CGP was cost-effective at the assumed WTP threshold. Conclusion For Chinese patients with L/M NPC, adding Chinese-developed anti-PD-1 antibody camrelizumab to the first-line GP chemotherapy may be cost-effective.
Open AccessCost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
Objective This study aimed to investigate the cost-effectiveness of adding Chinese-developed anti-PD-1 antibody camrelizumab to first-line platinum-doublet chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (L/M NPC) from the perspective of Chinese healthcare system. Design A Markov model consisting of four health states, progression-free survival, first progression survival, second progression survival and death, was built to simulate 3-week patient transitions over a 20-year horizon. A direct comparison between first-line camrelizumab in combination with gemcitabine plus cisplatin and gemcitabine plus cisplatin was performed by calculating transition probabilities from the CAPTAIN-1st trial. Costs and utilities were collected from the local public database and literature. One-way and probabilistic sensitivity analyses were employed to evaluate the robustness of the model. Setting The Chinese healthcare system perspective. Participants A hypothetical cohort of Chinese patients with pathologically diagnosed L/M NPC who had an Eastern Cooperative Oncology Group performance status of 0 or 1. Interventions First-line camrelizumab in combination with camrelizumab and gemcitabine plus cisplatin (CGP) versus gemcitabine plus cisplatin (GP). Primary outcome measure Cost, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER). Results The baseline analysis demonstrated that, compared with first-line GP, first-line CGP yields an effectiveness increase of 0.26 QALY, accompanied by an increment of US$6137.59 in healthcare cost. This results in an ICER of US$23 482.32/QALY. With the willingness-to-pay (WTP) threshold for a QALY set at US$37 654.50, first-line CGP proves to be cost-effective in 97.20% of the iterations. Deterministic sensitivity analyses indicated that the uncertainty in model parameters had no substantial effect on our results. Probability sensitivity analysis indicated that CGP was cost-effective at the assumed WTP threshold. Conclusion For Chinese patients with L/M NPC, adding Chinese-developed anti-PD-1 antibody camrelizumab to the first-line GP chemotherapy may be cost-effective.
- Open Access
- 15 May 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (7) , 737-744
Percutaneous closure of ventricular septal rupture after myocardial infarction: A retrospective study of 81 cases
Objective: To investigate the efficacy and safety of percutaneous closure of ventricular septal rupture (VSR) after acute myocardial infarction (AMI).Methods: This retrospective study included 81 patients who underwent transcatheter closure for postinfarction VSR. We analyzed clinical data from hospitalization and the 30‐day follow‐up, compared clinical data from the survival and death groups, and explored the best closure time and the safety and efficacy of occlusion. The risk factors for death at 30 days were analyzed by logistic regression.Results: C‐reactive protein (CRP), white blood cell counts, N‐terminal pro brain natriuretic peptide (NT‐ProBNP), and aspartate aminotransferase were higher in the death group than in the survival group (p < .01), with a higher rate of application of vasoactive drugs, and a shorter time from AMI to operation (p < .05). At 30 days postocclusion, 19 patients (23.5%) had died. The mortality rate was significantly lower for operation performed 3 weeks after AMI than for operation performed within 3 weeks of AMI (12.5% vs. 48%, p < .001). Devices were successfully implanted in 76 patients, with 16 (21.1%) operation‐related complications and 12 (15.8%) valve injuries. Cardiac function improved significantly (p < .001) at discharge (N = 66) and 30 days after procedure (N = 62). Qp/Qs and pulmonary artery systolic pressure decreased significantly, while aortic systolic pressure increased significantly (p < .001). Additionally, EF and LVDd improved (p < .05) after occlusion. Increases in CRP and NT‐ProBNP were risk factors for death at 30 days after closure (p < .05).Conclusion: Percutaneous VSR closure can be a valuable treatment option for suitable patients with VSR.
- 15 May 2023
- Published by Wiley in Clinical Cardiology
- Vol. 46 (7) , 737-744
Open AccessPercutaneous closure of ventricular septal rupture after myocardial infarction: A retrospective study of 81 cases
Objective: To investigate the efficacy and safety of percutaneous closure of ventricular septal rupture (VSR) after acute myocardial infarction (AMI).Methods: This retrospective study included 81 patients who underwent transcatheter closure for postinfarction VSR. We analyzed clinical data from hospitalization and the 30‐day follow‐up, compared clinical data from the survival and death groups, and explored the best closure time and the safety and efficacy of occlusion. The risk factors for death at 30 days were analyzed by logistic regression.Results: C‐reactive protein (CRP), white blood cell counts, N‐terminal pro brain natriuretic peptide (NT‐ProBNP), and aspartate aminotransferase were higher in the death group than in the survival group (p < .01), with a higher rate of application of vasoactive drugs, and a shorter time from AMI to operation (p < .05). At 30 days postocclusion, 19 patients (23.5%) had died. The mortality rate was significantly lower for operation performed 3 weeks after AMI than for operation performed within 3 weeks of AMI (12.5% vs. 48%, p < .001). Devices were successfully implanted in 76 patients, with 16 (21.1%) operation‐related complications and 12 (15.8%) valve injuries. Cardiac function improved significantly (p < .001) at discharge (N = 66) and 30 days after procedure (N = 62). Qp/Qs and pulmonary artery systolic pressure decreased significantly, while aortic systolic pressure increased significantly (p < .001). Additionally, EF and LVDd improved (p < .05) after occlusion. Increases in CRP and NT‐ProBNP were risk factors for death at 30 days after closure (p < .05).Conclusion: Percutaneous VSR closure can be a valuable treatment option for suitable patients with VSR.
- Open Access
- 17 October 2022
- Published by Hindawi Limited in Cardiovascular Therapeutics
- Vol. 2022, 1-9
Comparison between Cardiac CTA and Echocardiography for Assessment of Ventricular Septal Rupture Diameter and Its Effect on Transcatheter Closure
Objective. This study is aimed at comparing cardiac computed tomographic angiography (CTA) with echocardiography in the assessment of ventricular septal perforation diameter. Methods. A total of 44 ventricular septal rupture (VSR) patients undertaking transcatheter occlusion were included and randomly divided into the CTA group and echocardiography group with a 1 : 1 ratio. Clinical data, operation-related data, and 30 d follow-up data were collected and analyzed. Results. Incidence of closure failure, occluder displacement, poor occluder molding, and occluder waist diameter shrinkage between the two groups were not statistically different. The mean residual shunt volume in the echocardiography group (4.2 (3.1, 5.9) mm) was significantly higher than that in the CTA group (2.1 (0, 4.0) mm) with a value of 0.005. However, no significant differences were found in all-cause mortality and incidence of operative complications within 30 days after surgery. Within the CTA group, the correlation was strongest between postoperative occluder diameter and long diameter measured by CTA with a correlation coefficient of 0.799 and , followed by the correlation between postoperative occluder diameter and mean diameter measured by CTA with a correlation coefficient of 0.740 and . The diameter measured by echocardiography was not correlated to postoperative occlude diameter. Conclusion. Assessment of VSR diameter by cardiac CTA is more accurate than by echocardiography.
- 17 October 2022
- Published by Hindawi Limited in Cardiovascular Therapeutics
- Vol. 2022, 1-9
Open AccessComparison between Cardiac CTA and Echocardiography for Assessment of Ventricular Septal Rupture Diameter and Its Effect on Transcatheter Closure
Objective. This study is aimed at comparing cardiac computed tomographic angiography (CTA) with echocardiography in the assessment of ventricular septal perforation diameter. Methods. A total of 44 ventricular septal rupture (VSR) patients undertaking transcatheter occlusion were included and randomly divided into the CTA group and echocardiography group with a 1 : 1 ratio. Clinical data, operation-related data, and 30 d follow-up data were collected and analyzed. Results. Incidence of closure failure, occluder displacement, poor occluder molding, and occluder waist diameter shrinkage between the two groups were not statistically different. The mean residual shunt volume in the echocardiography group (4.2 (3.1, 5.9) mm) was significantly higher than that in the CTA group (2.1 (0, 4.0) mm) with a value of 0.005. However, no significant differences were found in all-cause mortality and incidence of operative complications within 30 days after surgery. Within the CTA group, the correlation was strongest between postoperative occluder diameter and long diameter measured by CTA with a correlation coefficient of 0.799 and , followed by the correlation between postoperative occluder diameter and mean diameter measured by CTA with a correlation coefficient of 0.740 and . The diameter measured by echocardiography was not correlated to postoperative occlude diameter. Conclusion. Assessment of VSR diameter by cardiac CTA is more accurate than by echocardiography.